Trial Profile
A Two-Stage, Randomized, Double-Blind, Dose-Ranging, Phase 2 Trial to Evaluate the Safety and Efficacy of UB-621 on HSV Shedding in Adults With Recurrent Genital HSV-2 Infection
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Oct 2022
Price :
$35
*
At a glance
- Drugs UB 621 (Primary)
- Indications Herpes genitalis; Herpes simplex virus type 2 infections
- Focus Therapeutic Use
- Sponsors United BioPharma
- 29 Sep 2022 Planned End Date changed from 30 Jun 2023 to 30 Jun 2024.
- 29 Sep 2022 Planned primary completion date changed from 30 Jun 2023 to 30 Jun 2024.
- 29 Sep 2022 Planned initiation date changed from 1 Jun 2022 to 1 Jun 2023.